SCHEMBL2561465

SCHEMBL2561465

CNc1ccc(-c2nc(N3CCOCC3)c3sc(CCN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 19/20 0.86
HDAC2 Q92769 7/20 0.86
HDAC10 Q969S8 7/20 0.86
HDAC11 Q96DB2 7/20 0.86
HDAC3 O15379 6/20 0.86
HDAC6 Q9UBN7 6/20 0.69
HDAC4 P56524 5/20 0.69
HDAC7 Q8WUI4 5/20 0.69
HDAC8 Q9BY41 5/20 0.69
HDAC9 Q9UKV0 5/20 0.69
HDAC5 Q9UQL6 5/20 0.69
NCOR2 Q9Y618 5/20 0.69
PIK3CA P42336 4/20 0.69
PIK3CD O00329 3/20 0.69
PIK3CB P42338 2/20 0.69
MTOR P42345 2/20 0.69
PIK3R1 P27986 2/20 0.69
PIK3CG P48736 2/20 0.69
PRKDC P78527 1/20 0.69
KCNH2 Q12809 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1284514 0.93 HDAC1 (1.00) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL29369531 0.93 HDAC1 (1.00) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL2563916 0.89 HDAC1 (0.69) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL2558754 0.89 HDAC1 (0.86) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL1621542 0.87 HDAC1 (0.82) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL2559157 0.87 HDAC1 (0.71) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL1622569 0.87 HDAC1 (0.78) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL30130772 0.85 HDAC1 (0.86) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL1284625 0.85 HDAC1 (0.86) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL28672556 0.85 HDAC1 (0.86) HDAC1HDAC2HDAC10HDAC11HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2557923-A1 TREATMENT OF CANCERS HAVING K-RAS MUTATIONS Curis, Inc. (US) 2013-02-20 EP disclosed
WO-2011130628-A1 TREATMENT OF CANCERS HAVING K-RAS MUTATIONS CURIS, INC. (US) 2011-10-20 WO disclosed